Licensing status

Publication and contact information


Non-small cell lung cancer (NSCLC)

Angiotensinogen (AGT); angiotensin-converting enzyme (ACE)

Patient tissue and mouse studies suggest ACE inhibitors could help treat NSCLC in patients with angiotensin II-overexpressing tumors. In a histological analysis of biopsies from 44 patients with NSCLC, 16 showed increased expression of the angiotensin II precursor AGT. In a genetic mouse model for NSCLC, the ACE inhibitor Vaseretic enalapril, which inhibits AGT cleavage and angiotensin II production, slowed tumor progression and increased survival compared with a control compound. Next steps include testing enalapril in combination with cancer therapeutics and investigating the mechanisms of enalapril resistance.
Vaseretic enalapril is marketed by Merck & Co. Inc. to treat hypertension and congestive heart failure (CHF).

SciBX 6(6); doi:10.1038/scibx.2013.137
Published online Feb. 14, 2013

Unpatented; licensing status not applicable

Cortez-Retamozo, V. et al. Immunity; published online Jan. 17, 2013;
Contact: Mikael J. Pittet, Massachusetts General Hospital, Boston, Mass.